- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05825417
Pulmonale hypertensie: intensivering en personalisatie van combinatie Rx (PHoenix)
Een multicenter gerandomiseerde cross-over studie van ziektespecifieke therapie bij patiënten met pulmonale arteriële hypertensie (PAH) geïmplanteerd met pulmonale arteriële druk en apparaten voor hartritmebewaking (CardioMEMS/ConfirmRx)
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Sheffield, Verenigd Koninkrijk, S10 2JF
- Sheffield Teaching Hospitals NHS FT
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusiecriteria:
- In staat om geïnformeerde toestemming te geven
- Leeftijd 18-80 jaar
- PAH die idiopathisch, erfelijk of geassocieerd met medicijnen, toxines of bindweefselziekte is
- Stabiel PAH-therapeutisch regime bestaande uit elke combinatie van ERA en PDE5i gedurende ten minste 1 maand voorafgaand aan screening (tenzij de therapie niet kan worden verdragen)
- WHO functionele klasse III
- Rust mPAP ≥20 mmHg, pulmonale capillaire wigdruk ≤15 mmHg, pulmonale vasculaire weerstand ≥2 Wood Units gemeten door middel van rechterhartkatheterisatie op het moment van diagnose
- 6MWT >50m bij binnenkomst
- Geschatte glomerulaire filtratiesnelheid (eGFR)>30 ml/min/1,73 m² bij binnenkomst (bijlage C)
- Ontoereikende behandelingsrespons (klinisch vastgesteld)
Uitsluitingscriteria:
- Kan geen geïnformeerde toestemming geven
- Zwangerschap
- Niet-uitgelokte longembolie (op elk moment)
- Acute infectie bij screening (herscreening is toegestaan)
- PAH door humaan immunodeficiëntievirus, portale hypertensie, schistosomiasis, aangeboren hartziekte
- Pulmonale hypertensie als gevolg van linkerhart-, long-, trombo-embolische of onduidelijke/multifactoriële ziekte (Groep II-V)
- Kan aspirine of P2Y12-remmer niet verdragen
- Overgevoeligheid voor selexipag of riociguat
- Klinisch significante nierziekte (eGFR≤30 ml/min/1,73m2)
- Bloedarmoede (hemoglobine <10 g/dl)
- Linkszijdige hartaandoening en/of klinisch significante hartaandoening, inclusief maar niet beperkt tot een van de volgende: aorta- of mitralisklepaandoening groter dan milde aorta-insufficiëntie; milde aortastenose; milde mitralisklepstenose; of matige mitralisinsufficiëntie
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm A (selexipag/riociguat)
Baseline - vastgestelde PDE/ERA-therapie Week 1 - start OPA (PDE/ERA/OPA-therapie) Week 2-12 - optitratie van OPA tot maximale therapie (PDE/ERA/OPA-therapie) Week 13-14 - verminder OPA (PDE/ERA /OPA-therapie) Week 15 - wash-out OPA (PDE/OPA-therapie) Week 16 - wash-out PDE (ERA-therapie) Week 17 - start sGCS (ERA/sGCS-therapie) Week 18-27 - optitratie van sGCS tot maximale therapie (ERA/sGCS behandeling)
|
Als arm A - Optitratie naar maximaal getolereerde dosis gevolgd door de-escalatie Als arm B - Optitratie naar maximaal getolereerde dosis gevolgd door observatie, aanpassing of overgang naar goeddunken van het verantwoordelijke zorgteam waar nodig.
Andere namen:
Als arm A - Optitratie naar maximaal getolereerde dosis gevolgd door de-escalatie Als arm B - Optitratie naar maximaal getolereerde dosis gevolgd door observatie, aanpassing of overgang naar goeddunken van het verantwoordelijke zorgteam waar nodig.
Andere namen:
Implantatie en bewaking op afstand tot stand gebracht met door de patiënt geïnitieerde dagelijkse metingen
Implantatie en monitoring op afstand tot stand gebracht met geautomatiseerde dagelijkse metingen / downloads
|
|
Actieve vergelijker: Arm B (riociguat/selexipag)
Baseline - vastgestelde PDE/ERA-therapie Week 1 - wash-out PDE (alleen ERA-therapie) Week 2 - start sGCS (ERA/sGCS-therapie) Week 3-12 - verhoging van sGCS naar maximale therapie (ERA/sGCS-therapie) Week 13 - verminder sGCS (ERA/sGCS-therapie) Week 14 - sGCS verminderen en uitwassen (ERA-therapie) Week 15 - PDE starten (PDE/ERA-therapie) Week 16 - OPA starten (PDE/ERA/OPA-therapie) Week 17-27 - optitratie van OPA tot maximale therapie (PDE/ERA/OPA therapie)
|
Als arm A - Optitratie naar maximaal getolereerde dosis gevolgd door de-escalatie Als arm B - Optitratie naar maximaal getolereerde dosis gevolgd door observatie, aanpassing of overgang naar goeddunken van het verantwoordelijke zorgteam waar nodig.
Andere namen:
Als arm A - Optitratie naar maximaal getolereerde dosis gevolgd door de-escalatie Als arm B - Optitratie naar maximaal getolereerde dosis gevolgd door observatie, aanpassing of overgang naar goeddunken van het verantwoordelijke zorgteam waar nodig.
Andere namen:
Implantatie en bewaking op afstand tot stand gebracht met door de patiënt geïnitieerde dagelijkse metingen
Implantatie en monitoring op afstand tot stand gebracht met geautomatiseerde dagelijkse metingen / downloads
|
|
Actieve vergelijker: Arm C : Sotatercept
Baseline - established background therapy; initiate sotatercept 0.3 mg/kg Week 3 - evaluate safety parameters (Hb/platelets) & uptitrate sotatercept to target dose 0.7 mg/kg . Weeks 6, 9, 12, 15, 18, 21 - maintenance sotatercept 0.7 mg/kg every 3 weeks with safety monitoring Week 24 - final maintenance dose and endpoint assessments |
Implantatie en bewaking op afstand tot stand gebracht met door de patiënt geïnitieerde dagelijkse metingen
Implantatie en monitoring op afstand tot stand gebracht met geautomatiseerde dagelijkse metingen / downloads
Subcutaneous injection of sotatercept administered once every 3 weeks for 24 weeks.
Treatment is initiated at a starting dose of 0.3 mg/kg at Week 0 and escalated at Week 3 to a target maintenance dose of 0.7 mg/kg, contingent on body weight, clinical response, and pre-dose safety parameters (haematoglobin and platelet counts).
Maintenance dosing at 0.7 mg/kg continues every 3 weeks through Week 21, alongside continuous daily remote hemodynamic and physiological monitoring via implanted CardioMEMS and cardiac rhythm devices.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Right Ventricular Stroke Volume (RVSV) flow on each therapy measured by MRI RSVS (flow) on each therapy measured by MRI
Tijdsspanne: Baseline to Week 12 of each crossover period
|
This provides a robust, objective assessment of clinical efficacy which, if met, will mean that a change in therapy has provided a clinically meaningful change in physiology
|
Baseline to Week 12 of each crossover period
|
|
Daily Hemodynamic Detection of Treatment Response During Sotatercept Escalation
Tijdsspanne: Baseline (Week 0) through Week 24
|
Within-patient changes in continuous, remote-monitored Total Pulmonary Resistance (TPR), mean Pulmonary Artery Pressure (mPAP), Cardiac Output (CO), Stroke Volume (SV), and Heart Rate (HR) detected by the CardioMEMS sensor following treatment escalation with sotatercept, correlated with end-of-treatment RVSV measured by cardiac MRI.
|
Baseline (Week 0) through Week 24
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Haemodynamics - Total Pulmonary Resistance (TPR)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
Change in TPR (Woods Units) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
|
Haemodynamics - mean Pulmonary Artery Pressure (mPAP)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
Change in mPAP (mmHg) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
|
Haemodynamics - Cardiac Output (CO)
Tijdsspanne: Part 1 : From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
Change in CO (L/min) on each therapy to determine clinical efficacy
|
Part 1 : From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
|
Haemodynamics - Cardiac Index
Tijdsspanne: Part 1 : From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
Change in cardiac index (L/min/m^2) on each therapy to determine clinical efficacy
|
Part 1 : From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
Haemodynamics - Stroke Volume (SV)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
Change in SV (mL) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
|
Haemodynamics - Heart Rate (HR)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
Change in HR (bpm) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
|
6 Minute Walk Test
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
Change on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
|
NTpro-BNP
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
Change on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks.
|
|
MRI - Right Ventricular Ejection Fraction (RVEF)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
RVEF (%) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
MRI - Right Ventricular End Systolic Volume (RVESV)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
RVESV (mL/m^2) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
MRI - Right Ventricular End Diastolic Volume (RVEDV)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
RVEDV (mL/m^2) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
MRI - Right Ventricular Stroke Volume (RVSV)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
RVSV (mL) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
MRI - Left Ventricular Volume Fraction (LVEF)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
LVEF (%) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
MRI - Left Ventricular End Systolic Volume (LVESV)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
LVESV (mL/m^2) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
MRI - Left Ventricular End Diastolic Volume LVEDV
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
LVEDV (mL/m^2) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
MRI - Left Ventricular Stroke Volume (LVSV)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
LVSV (mL) on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
MRI - Left Ventricular Stroke Volume (LVSV) flow
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
LVSV flow on each therapy to determine clinical efficacy
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
Patient Reported Outcomes (PRO) - Quality of Life (QoL) (EmPHasis-10)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
Change of QoL score on each therapy to determine clinical efficacy.
This will be done using EmPHasis-10 questionnaire (10 questions using a 0 (poor) - 5 (good) scale)
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
Patient Reported Outcomes (PRO) - Medication Compliance (PHoenix PRO)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks
|
Change of medication compliance score on each therapy to determine clinical efficacy.
This will be done using PHoenix PRO questionnaire (10 questions using a 0 (poor) - 5 (good) scale)
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks
|
|
Patient Reported Outcomes (PRO) - Medication Side Effects
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
Change of medication side effects on each therapy to determine clinical efficacy.
This will be done using PHoenix Medication side effects questionnaires (4 Yes/No or Better/Worse style questions)
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
Patient Reported Outcomes (PRO) - Depression symptoms (GAD-2/7)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
Change of depression symptoms on each therapy to determine clinical efficacy.
This will be done using the GAD-2/7 questionnaire (2 screening questions to determine if symptoms present.
If present, 7 additional questions to determine level of depression using a 0 (not at all) - 3 (nearly every day) scale)
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
Patient Reported Outcomes (PRO) - Anxiety symptoms (PHQ-2/9)
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
Change of anxiety symptoms on each therapy to determine clinical efficacy.
This will be done using the PHQ-2/9 questionnaire (2 screening questions to determine if symptoms present.
If present, 9 additional questions to determine level of anxiety using a 0 (not at all) - 3 (nearly every day) scale)
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
WHO functional class
Tijdsspanne: Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
Change on each therapy to determine clinical efficacy.
Functional assessment of PAH will be made according to the WHO classification system: Class I - Patients with PAH without limitation of physical activity.
Ordinary physical activity does not cause increased dyspnoea or fatigue, chest pain, or near syncope / Class II - Patients with PAH resulting in slight limitation of physical activity.
No discomfort at rest.
Normal physical activity causes increased dyspnoea or fatigue, chest pain, or near syncope / Class III - Patients with PAH resulting in marked limitation of physical activity.
There is no discomfort at rest.
Less than ordinary activity causes increased dyspnoea or fatigue, chest pain, or near syncope / Class IV - Patients with PAH with inability to carry out any physical activity without discomfort.
Indications of manifest right heart failure.
Dyspnoea and/or fatigue may even be present at rest.
Discomfort is increased by the least physical activity.
|
Part 1: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks Part 2: From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
EuroQoL-5D-5L
Tijdsspanne: Part 2 only : From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
The EuroQoL-5D-5L is included for future health economic evaluation of sotatercept.
(free for non-commercial use
|
Part 2 only : From baseline and area under the curve to 3 weeks, 6 weeks, 12 weeks, 18 weeks, and 24 weeks
|
|
PHoenix UTAUT questionnaire
Tijdsspanne: Part 1 only: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks
|
Evaluation of remote monitoring technology and devices.
|
Part 1 only: From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Alexander Rothman, MD / PhD, University of Sheffield
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- STH21653
- MR/W026279/1 (Ander subsidie-/financieringsnummer: UKRI Medical Research Council)
- 325120 (Andere identificatie: IRAS)
- MISP 102663 (Ander subsidie-/financieringsnummer: MERCK SHARP & DOHME(UK) LIMITED [MSD])
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Onderzoeksmonsters worden overgebracht naar de Sheffield Biorepository zonder identificeerbare persoonlijke gegevens.
Gegevens worden verzameld en gehost en verwerkt door University of Oxford (gegevensleverancier). Geautoriseerde gegevensverstrekkers omvatten, maar zijn niet beperkt tot PI's en gedelegeerd personeel; Deelnemers; en Core Imaging Laboratory. De proefmanager leidt het gegevensverificatieproces. Monitoringgegevens op afstand worden beheerd via Merlin.net systeem (Apparaatleverancier - Abbott). Gepseudonimiseerde gegevens worden vervolgens veilig overgedragen, bewaard, geanalyseerd en gearchiveerd aan de Universiteit van Glasgow (verwerker). Gegevens worden ook overgedragen aan de University of Sheffield en Newcastle University (verwerker) voor studieanalyse.
De University of Sheffield is eigenaar van alle rechten, aanspraken en belangen in en op alle gegevens van de University of Sheffield. Voor de doeleinden van de wetgeving inzake gegevensbescherming is Sheffield Teaching Hospitals (sponsor) de gegevensbeheerder.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .